JOHNSON & JOHNSON is 57.6x more valuable than ARROWHEAD PHARMACEUTICALS, INC. by market capitalization ($574.10 B vs $9.96 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ARWR | JNJ |
|---|---|---|
| Market cap | $9.96 B | $574.10 B |
| US-listed rank | #941 | #20 |
| Revenue (latest FY) | $829.45M | $94.19B |
| Net income (latest FY) | -$1.63M | $26.80B |
| Net margin | -0.2% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 1,347 | 984 |
JOHNSON & JOHNSON is 57.6x more valuable than ARROWHEAD PHARMACEUTICALS, INC. by market capitalization ($574.10 B vs $9.96 B).
In their latest fiscal years, ARROWHEAD PHARMACEUTICALS, INC. reported $829.45M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: ARROWHEAD PHARMACEUTICALS, INC. and JOHNSON & JOHNSON, or browse the full rankings.